At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 211 enrolled
Drug / intervention
Rituximab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
In Brief
A Phase 3 clinical trial evaluating Vitamin D, Rituximab, and 1 other intervention for Follicular Lymphoma and 3 related conditions. Completed, enrolled 211 participants across 7 sites.
Detailed Summary
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
CountriesUnited States
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartSep 2017
Primary CompletionJul 2023
Study CompletionJul 2024
TodayJul 2026
First PostedMar 13, 2017
Enrollment StartSep 7, 2017
Primary CompletionJul 21, 2023
Study CompletionJul 2, 2024
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 9.3 years ago
Interventions
Vitamin Ddietary
vitamin D3 2,000 IU daily
Rituximabbiological
Administered weekly x 4
Placeboother
methylcellulose